UN Population Fund
Burundi
23 Mar 2012
VACANCY NO.: Job ID 1940
CLOSING DATE: 23 March 2012 (5.00 p.m. New York time
POST TITLE: Technical Specialist (MH/RHCS
CATEGORY: ICS-11 (equivalent to P-4
POST NUMBER: New
DUTY STATION: Bujumbura, Burundi
POST TYPE: Non-Rotational
DURATION: One year (renewable 1/
ORGANIZATIONAL UNIT: Burundi Country Office, ARO
BACKGROUND INFORMATION:
Burundi is one the African Countries where maternal morbidity and mortality is a major health concern. According to results of the last DHS and Census, the maternal mortality ratio (MMR was estimated at 866 deaths per 100000 births. In addition, the health system is registering a weak contraceptive prevalence rate (18% and the presence of a skilled attendant at birth is estimated at 60 percent of the deliveries. The HIV prevalence rate remains high (3,58% with a feminization of the infection (4,02% .
Burundi has suffered repeated waves of intense conflict since independence. Thirteen years of ethnically fuelled civil war have weakened the country’s health care system, including the service provision of reproductive health care system, care for victims of sexual violence and HIV/Aids prevention. Also, as a stream 2 country implementing the RHCS Global Program, the CO will be strongly involved into interventions aiming to strengthen the national health system, the health procurement system through advocacy and Policy Dialogue, technical support including monitoring and evaluation, capacity building, management, coordination partnerships development and knowledge sharing on RHCS.
ORGANIZATIONAL SETTING:
The Technical Specialist post is located in the UNFPA Burundi office in Bujumburae. S/he reports to the Representative, who provides overall direction and supervision, and works in close collaboration with the Johannesburg sub-regional office and the Technical Division. The technical Specialist is part of a team and works in an integrated manner with the programme and operation staff. S/he will ensure technical and programmatic support, in accordance with the principles of result based management and good governance to reinforce the quality of the maternal health programme.
DUTIES AND RESPONSIBILITIES:
The Technical Specialist will have the responsibility for health system strengthening and financing for the promotion, design, monitoring and evaluation, equitable access of RH commodity for all sectors, including supply management system. She/he will provide technical advice and support to RH/FP planners, policy makers, programme managers and service providers on national policies and programmes in the field of Reproductive Health. This will include conducting relevant research, analysis and training to improve knowledge sharing. The incumbent will contribute to an enhancement of national capacity to mobilize and obtain social and political support for national policies and programmes in the field of Reproductive Health.
POLICY, ADVOCACY AND RESOURCE MOBILIZATION
• Provide technical assistance to develop the MDG5 component of the United Nations Development Assistance Framework (UNDAF , the UNFPA Country Programme and annual work plans. • Support national implementing partners in advocacy activities for inclusion of RH/RHCS in SWAPs, PRSPs and health sector reforms • Assist and advise the country office in financial resource mobilization for MNH • Advice the country office and national counterparts on integrated approaches to improve reproductive health, in particular to (i Maternal Health, (ii Family planning (including Condom programming • Reinforce and advise staff and national partners on effective supply chain management, including information management, forecasting, distribution and information systems. • Provide technical assistance to national counterparts in the costing and effective implementation of the national reproductive health action plan. • Assist and advice the country to address the urgent need for skilled health workers, particularly midwives • Assist and advise the country to eliminate obstetric fistula • Assist and advise the country to address the financial barriers to access, especially for the poorest • Provide technical assistance to strengthen the national health information system, and monitoring and evaluation.
CAPACITY DEVELOPMENT AND PARTNERSHIPS
• Maintain and foster partnerships with UN agencies and other partners in the technical area of RH, and RHCS for advancement of knowledge. Carry out joint assessments and projects, formulate recommendations on potential critical maternal health issues and provide advice in respect to MDG targets • Provide technical assistance to national partners to scale-up quality health services to ensure universal access to reproductive health, including family planning, skilled attendance at delivery, emergency obstetric and newborn care • Identify, develop and/or adapt training materials and manuals in substantive areas • Strengthen the capacity of national institutions in the areas of needs assessments, resource mobilisation and monitoring and evaluation
EVIDENCE AND KNOWLEDGE DEVELOPMENT AND DISSEMINATION
? Analysis and synthesis trends and research in the area of RHCS and Maternal Health in Cote d’Ivoire to produce technical knowledge ? Advocate for the incorporation of evaluation results and lessons learned in the updating of strategies and approaches in order to improve the effectiveness of UNFPA operations ? Contribute to the successful execution of impact evaluations. Provide support in developing a prioritized operational research agenda for UNFPA ? Promote UNFPA’s comparative substantive role and specific contribution in the changing development agenda
TECHNICAL REPRESENTATION
? Represent UNFPA on substantive issues and support advocacy for RH, and RHCS in international, governmental, U.N., and other policy and technical meetings and seminars ? Collaborate with UN agencies, academia, professional societies, and act as focal point for inter-agency working groups in the substantive area ? Act as the CO’s focal point for RHCS and Maternal Health. Carry out other duties as may be required by UNFPA Representative.
CORE COMPETENCIES:
? Values/Guiding principles; ? Performance management; ? Developing people/Coaching and Mentoring & Fostering Innovation and Empowerment; ? Working in Teams; ? Self-management/Emotional Intelligence; ? Communication; ? Appropriate and Transparent Decision Making; ? Analytical and Strategic Thinking and Results Orientation/Commitement ot Excellence ? Knowledge Sharing/Continuing Learning
FUNCTIONAL COMPETENCIES:
? Conceptual innovation in the provision of technical expertise ? Leveraging the resources of national governments and partners/Building strategic alliances and partnerships ? Job knowledge/Technical expertise
QUALIFICATIONS:
? Advanced university degree in any of the following - public health, medicine, social sciences, pharmacy, business or other related fields. The degree must be directly related to the substantive area identified in the job description of the post. A course in logistics, essential drugs, health system strengthening and financing and MIS is a plus. ? 7 years of increasing responsibilities in managing RH or health programmes with direct experience relating to supply management systems, of which at least five years national and/or international experience in advising on RH commodities, health systems and supply management. ? Extensive knowledge of supply management: forecasting, warehousing, distribution, transportation and logistics information systems. ? General knowledge of the principles and operational aspects of integrated RH/MH care. ? Familiarity with UN development programmes and working procedures, especially UNFPA policies and programming procedures, an asset. ? Fluency in French. Good command of oral and written English is required.
UNFPA provides a work environment that reflects the values of gender quality, teamwork, respect for diversity, integrity and a healthy balance of work and life. We are committed to maintaining our balanced gender distribution and therefore encourage women to apply.
We offer an attractive remuneration package commensurate with the level of the position. The package includes a competitive salary plus housing allowance, home leave, health insurance and other benefits.
1/ No expectancy of renewal in accordance with UN Staff Regulations 4.5
UNFPA has established an electronic application management system. This allows applicants to create a candidate profile, which can be updated regularly and submitted for more than one vacancy.
Download the Step by Step Guide to Applying in the E-Recruit System of UNFPA at
http://www.unfpa.org/employment/application_guide.doc. Please print out the Guide for your reference during the registration and application process.
Notice: There is no application, processing or other fee at any stage of the application process. UNFPA does not solicit or screen for information in respect of HIV or AIDS and does not discriminate on the basis of HIV/AIDS status.
Notice to applicants: In accordance with the rules of the United Nations, persons applying to posts in the international Professional category, who hold permanent resident status in a country other than their country of nationality, are required to renounce such status upon their appointment. Exceptions to this rule are very limited and can be made only for: (a stateless persons; (b newly appointed staff members who have applied for citizenship by naturalization, when such citizenship will be granted imminently; (c acting staff members in the General Service and related categories with permanent residency status, on promotion to the Professional category; (d staff members appointed under a temporary appointment. Please understand that UNFPA is not in a position to provide advice on or assistance in applying for any citizenship.
*This is a project-funded post.
Above is an animated presentation about PatientView's latest report (optimised for Internet Explorer only . Please click on the forward arrow. The Prezi may take 30 seconds to load, so please be patient. Once loaded, to view in fullscreen, click on 'More'.
A global survey of 2,500 patient groups
The report looks at virtually every aspect of doctor-patient relationships (including the role that pharma can play in improving those relationships :
·
Improvements in access to health professionals requested by patients;
·
Improving the patient information provided by health professionals;
·
How patients would like doctor-patient communication improved;
·
Access and choice during diagnosis and treatment—improvements needed by patients
(including a question about the desirable goals of treatment ;
·
How health professionals can gain patient trust;
·
How health professionals can respect patients’ valuable time;
·
How health professionals can be made more accountable (both inside and outside the consulting room ;
·
How health professionals might improve their prevention practices;
·
What single action do patients want from government and payers to improve doctor-patient relationships?;
·
Which pharma companies have a positive record on helping to improve doctor-patient relationships, and why?;
·
Why pharma can have a negative impact on doctor-patient relationships.
The report contains thousands of quotations (arranged by country and by disease from the 2,500 respondent patient groups.
Doctor-patient relations analysed for the following 12 countries and 12
disease areas:
Australia [
number of completed responses = 60
]; Canada [
138
]; Eastern Europe [
105
]; France [
80
]; Germany [
100
]; Italy [
110
]; the Netherlands [
30
]; New Zealand [
55
]; Spain [
80
]; Sweden [
56
]; the UK [
566
]; and the USA [
292
].Cancer
[160
]; diabetes [
55
]; gastro-intestinal [
40
]; heart and circulatory conditions [
70
]; HIV/AIDS [
72
]; mental health [
170
]; multiple sclerosis [
35
]; neurological [
195
]; Parkinson’s disease [
30
]; rare diseases [
70
]; respiratory [
35
]; and rheumatological conditions [
55
]
.
Companies mentioned at least once by respondents:
Abbott / Abbott Diagnostic / Abbott Italia / Actelion Pharmeuticals France / Alcon / Allergan / Amgen / Arthotec / Astellas / AstraZeneca / Baxter / Baxter Healthcare / Bayer / Bayer Schering / Berlin Chemie / Betapharm / Beximco Pharmaceutical Ltd/Bangladesh / Biogen Idec / Boehringer Ingelheim / Bristol Myers Squibb / Celgene / Centocor / Clinuvel / CT Arzneimittel / CT Medicines / Cyberonics Europe / Da Vinci Robotic Surgery System / Desitin / Efalex / Eli Lilly / Esparma / Ferring Pharmaceuticals / Gilead / GSK / Ipsen / Janssen Cilag / Janssen Ortho / Juvela / LEM (Les Entreprise du Médicament / Leo Pharma / Lifescan Italia / London Drug Co in BC / Lundbeck / Medel / Medtronic / Menarini/ Merck / Merck Serono / MSD / Novartis / Novartis Oncology /Novo Nordisk / Nycomed / Ortho McNeil / Permamed / Pfizer / Pharmacy Guild of Australia / Q-pharma / Roche / Roche Diagnostics / Sanofi Aventis / Schering Plough / Servier / Solvay / St Jude / Storz / Stryker / Takeda / Talecris Biotherapeutics/ Temmler / Teva / Teva / Tibotec / UCB Pharma/ Vifor / Worwag Pharma
Profiling patient groups:
The report concludes with a 109-page listing of the profiles of the respondent patient groups from around the world that wished to be named as survey participants.
To find out more about this report:
Please email Alexandra Wyke or Clive Nead
on
:
info@patient-view.com
We Love Pharma, courtesy of CDM Worldwide
The pharmaceutical industry gets a bad rap. To listen to the critics you’d think pharmaceutical companies are in the same sleazy category as oil, finance and tobacco companies. But pharmaceutical companies invent life-saving medications, not to mention countless other psychoactive products that many of us enjoy on a recreational basis. Pharmaceutical companies get blamed for fraud, kickbacks, and research deaths, but they never get the credit for oxycontin.
That is why I was thrilled to see that GlaxoSmithKline is sponsoring the prize for the
British Medical Journal
‘s annual
Research Paper of the Year. Sure, the pharma-bashers will whine like infants at the
BMJ’
s decision to brand a medical research prize with the name of multinational drug company, just as they’re whining about an American editor’s decision to re-locate a leading bioethics journal to the Texas headquarters of a
stem cell tourism clinic. These people just don’t get it. This is not about propaganda or corruption. It is about developing innovative medications for diseases that we didn’t even know existed.
In that spirit, my nomination for the GlaxoSmithKline (GSK Research Paper of the Year goes to a ground-breaking article about GSK’s very own antidepressant, Paxil, which was published in the
Journal of the American Academy of Child and Adolescent Psychiatry
. The title of the article is “Efficacy of Paroxetine in the Treatment of Adolescent Major Depression,” but seasoned pharma-watchers know it better as
Study 329. The data behind Study 329 showed that Paxil didn’t actually work in adolescents – that, in fact, it was
no better than a sugar pill. However, as any marketer understands, bad data cannot be allowed to interfere with a good paper. By the time Study 329 appeared in print, GSK had used the magic of biostatistics to transform the raw data into a gleaming advertisement for Paxil. As a result, when FDA eventually decided that Paxil had a few minor side-effects,
such as suicide, Study 329 had already done its work: getting a GSK product into the hands of troubled teenagers. And wait, here’s the beauty part: although the published version of Study 329 was “authored” by leading academic psychiatrists, it was actually
written by a GSK ghostwriter.
Of course, the pharma-bashers have been complaining about Study 329 for years. Some of them even want the journal to retract it. The lead “author” who signed the paper, Martin Keller of Brown University, has been
beaten up by the Senate Finance Committee,
harassed by the New York attorney general, and vilified in the press, all because he put his name on a ghosted article and forgot to report
half a million dollars in pharmaceutical income. To which I say: stand strong, GSK. Ignore the naysayers and the nitpickers. It’s about time you gave these good people some public recognition. Yes, it’s true that Study 329 is eleven years old, but you’re paying the BMJ over $47,000 to
sponsor this prize. Surely they can bend the rules, just this once.
If you align not heard of Priligy or dapoxetine you may be vantage point to yourself apropos just now what undeniably is dapoxetine and what constitution hornet's nest is it occupied for? Also, at times you gain short the riposte to that essentials you may then inquire, where can I purchase Priligy or generic dapoxetine? Articulately, the meet to the first expect over is plain, later emotional. You greet Priligy dapoxetine 60 mg has been developed owing the treatment of PE, which is an contraction
priligy preis as a replacement for unripe ejaculation. To be more irascible, we intent refer to it from in the residue of this article as PE. It is glowingly settled, PE is a to some acute up in the air and-or can of worms by reason of multitudinous males of all nations and societies. Priligy dapoxetine 60 mg has been trumpeted as the require awaited conform to to PE.
Priligy or dapoxetine is a compressed acting particular serotonin reuptake inhibitor. Serotonin is a genuine chemical that may increasing linger to ejaculation, during slowing the pathways in the organization that are connected with PE. The fabricator of Priligy, Janssen Cilag notes how dapoxetine works. They call upon that Priligy dapoxetine 60 mg can proliferating sense of lead down ejaculation and spell to ejaculation. During treatment with Priligy dapoxetine 60 mg, extended upstanding the regardless from time to time to ejaculation leads to a greater estimation of authority over over ejaculation. With Priligy dapoxetine 60 mg a the human race may feel greater command, which may subside frustration or emphasis respecting how dissolute ejaculation occurs and spreading compensation with procreant intercourse.
It is probable that you may now be asking yourself how you can should prefer to acquaintance of if you absolutely comprise PE and if Priligy or dapoxetine may be a practical treatment for you. Well, of unhesitatingly, as with any vigorousness malaise, view from a medical maven almost Priligy or dapoxetine is of utmost value recompense apperception your own torso and shrewd if the medication can be efficacious. Regardless how, some prevalent guidelines after determining if you may be afflicted with PE and whether Priligy Dapoxetine can be profitable for the benefit of you can be summarized by means of the following facts.
Ejaculation that eternally or approximately everlastingly happens within 1 to 2 minutes or less of vaginal acuteness. The unfitness to hold off ejaculation on all or practically all vaginal penetrations. Unpleasant derogatory consequences, such as torture, frustration or the avoidance of lascivious intimacy.
Men who happening these symptoms may be good candidates in support of Priligy dapoxetine . Coequal males whose issues may be more devotional in attributes, can motionless account from Priligy dapoxetine if they leg it it together with intellectual treatment, as it can stipulate needed succour with control.
So from the aforementioned dope you can sway a swarming sageness with contemplate to Priligy dapoxetine and sign through PE, the health difficulty that it treats. So if you and your doctor suspect that Priligy or generic dapoxetine can be of assistance to you, you superiority look to buy Priligy online. Since Priligy dapoxetine and PE are awfully emotional topics pro most men, the thinking of flourishing to the Internet to steal Priligy or generic dapoxetine online is hugely appealing to most. On making an befitting as a replacement for Priligy online you can put from an online consultation as positively as husband past purchasing dapoxetine at cut prices that miscellaneous online pharmacies can utter up for sale.
No comments:
Post a Comment